Table 2 Pathologic response per protocol arm
Group | Letrozole, n = 24 | Letrozole/bevacizumab, n = 45 | ||
|---|---|---|---|---|
n (%) | 95% CI†| n (%) | 95% CI†| |
Pathologic CR (pCR) | none (0) | 0, 14.2% | 5^ (11) | 3.7%, 24.1% |
pCR and microscopic residual disease | none (0) | 0, 14.2% | 9 (20) | 9.6%, 34.7% |
pCR and microscopic residual disease—(ITT)* | none (0) | 0, 14.2% | 9 (18) | 8.6%, 31.4% |
Partial response | 9 (37.5) | 18.8%, 59.4% | 20 (44.4) | 29.6%, 60.0% |
Objective response rate | 9 (37.5) | 18.8%, 59.4% | 29 (64.4) | 48.8%, 78.1% |
Stable disease | 12 (50) | 29.1%, 70.9% | 13 (28.8) | 16.4%, 44.3% |
Progressive disease | 3 (12.5) | 2.7, 32.4% | 3 (6.6) | 1.4%, 18.3% |
Downstage (3/2 to 0/1) | 9 (37.5) | 18.8%, 59.4% | 20 (44.4) | 29.6%, 60.0% |
Node reversion (positive to negative) | 4/15 (26.6) | 7.8%, 55.1% | 10/25 (40) | 21.1%, 61.3% |